{"id":"W4387865238","doi":"10.1200/jco.23.02005","title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":931,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Takeda Oncology; Genentech; Menarini Group; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; Jounce Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; AstraZeneca; Novocure; Eisai Canada; Cholangiocarcinoma Foundation; F. Hoffmann-La Roche; Taiho Pharmaceutical; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Regeneron Pharmaceuticals; European Organisation for Research and Treatment of Cancer; Mersana Therapeutics; Karyopharm Therapeutics; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Trastuzumab; Immunohistochemistry; Clinical endpoint; Gastroenterology; Oncology; Surgery; Cancer; Breast cancer; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001753727,0.0007219521,0.001048108,0.0001923382,0.0002082547,0.0007142502,0.0003011519,0.0004724509,0.001331609],"category_scores_gemma":[0.0009854683,0.0001985958,0.0008045186,0.000229382,0.0004040637,0.0004321389,0.0002087087,0.001243649,0.0002627854],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007933261,"about_ca_system_score_gemma":0.0006857576,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005699217,"about_ca_topic_score_gemma":0.001412263,"domain_scores_codex":[0.9996344,0.0001918287,0.00002615789,0.00004969072,0.00004690533,0.00005093066],"domain_scores_gemma":[0.9993641,0.0001542992,0.0001861008,0.00003419631,0.00004058596,0.000220743],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7206991,0.01691626,0.06368087,0.0008715129,0.003111296,0.0004351881,0.0003470696,0.004293877,0.01873009,0.0002279227,0.007141156,0.1635456],"study_design_scores_gemma":[0.5305281,0.2918528,0.1554397,0.0001533074,0.002070789,0.001327893,0.0001391369,0.004300943,0.006132687,0.0003758319,0.007628632,0.00005017705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957266,0.002362277,0.0001447085,0.0001997704,0.00002827336,0.0002061637,0.0004508233,0.00002083636,0.0008605513],"genre_scores_gemma":[0.9960141,0.0009512624,0.0002447498,0.0002861237,0.00006782632,0.0001650526,0.001607505,0.000007601097,0.0006558032],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001753727,"threshold_uncertainty_score":0.009274721,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.161277714946747,"score_gpt":0.5034432526818972,"score_spread":0.3421655377351502,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}